Our Company

Amylyx is a Cambridge-based pharmaceutical company dedicated to the development of therapeutics for the treatment of neurodegenerative disorders. Guided by our core values, we incorporate unconventional approaches through strong partnerships with industry leaders, scientists, doctors and organizations. We work collaboratively across everything we do to positively impact the lives of patients and their families.

Our Story

“Why do neurons die?” Those four words, asked in a dorm room at Brown University in 2013, launched Amylyx into existence and began our journey to develop a novel therapeutic for Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases.

After methodically poring over an endless supply of scientific literature, founders Josh Cohen and Justin Klee decided the best way to prevent degradation in these diseases was to focus on preserving neurons. What started as a question became a clinical reality: Amylyx has since advanced its oral drug candidate, AMX0035, into clinical trials in ALS (CENTAUR; trial completed) and Alzheimer’s disease (PEGASUS; fully enrolled).

Every day at Amylyx we’re working to turn neurodegenerative diseases from rapidly progressing conditions into ones that can be managed medically. Together we can rewrite what’s possible.

Our Mission

It is our mission to one day end the suffering caused by neurodegenerative diseases. Every day we strive for better therapies. We question the unquestioned, yet we look for simple solutions.

Our Values

Icon: Person

Be Audacious

Patients are our true north; we envision new possibilities, boldly seek untried approaches and fearlessly innovate for them.

Icon: Question mark

Be Curious

By asking the right questions, listening and learning, we thrive in a culture of continuous improvement, driven by generously sharing knowledge, making each of us, and the company, better.

Icon: Hand Raised

Be Engaged

We can only understand patients’ needs when we understand their journey. By deeply engaging the patient and care provider communities, we know what’s needed.

Icon: Handshake

Be Accountable

Patients are waiting; they come first, and we have a responsibility to turn our most promising ideas into urgent action on their behalf.

Icon: Heart

Be Authentic

When we genuinely care about the work we do and the people with whom we work, we make Amylyx a place where breakthroughs for patients are possible.

Built on Connections

The neurology community is strong and collaborative, and we’re honored to be part of it. From advocacy groups to researchers to hospitals, working together is what enables innovation.  At the heart of everything we do are patients, their caregivers and their families, guiding us in the right direction to strengthen these connections as we connect the path to possible.


The organizations listed above are not being paid for the use of their trademarks on this website.


Amylyx was built on the foundation of audacious curiosity, relentless drive, and meaningful relationships. If that sounds like you, we’d love to talk.

Open Positions
Amylyx Pipeline

We are currently exploring the impact of our lead therapeutic AMX0035 as a treatment option for patients with ALS and Alzheimer’s disease.

Learn More